CBG vs THC: Non-Intoxicating vs Intoxicating
Put CBG and THC on the same receptor and they pull in opposite directions. THC (tetrahydrocannabinol) switches CB₁ on as a partial agonist, and that is where the cannabis high comes from; in lab studies CBG (cannabigerol) blocks the same receptor as an antagonist. Only THC intoxicates. The two also part ways on chemistry, legal status and the drug test, and the human research on CBG is still very thin. Established
Identity, chemistry, receptor mechanism and intoxication are verified science, so they appear as fact with a grade beside them. Claims about effects or benefits belong to whoever makes them; we hand them back with their limits attached, and we make a therapeutic claim for neither THC nor CBG. Grade ladder: the six-rung evidence ladder, with each chip linked to /evidence. Nothing here is medical or legal advice; the full disclaimer sits at the foot of the page.
Side by side
| Attribute | CBG (cannabigerol) | THC (tetrahydrocannabinol) |
|---|---|---|
| Intoxicating? | CBG (cannabigerol)No · Established | THC (tetrahydrocannabinol)Yes · Established |
| CB₁ receptor (pharmacology) | CBG (cannabigerol)Competitive antagonist that blocks the receptor (Cascio 2010) · Demonstrated · in vitro | THC (tetrahydrocannabinol)Partial agonist that activates the receptor · Established |
| Molecular formula | CBG (cannabigerol)C₂₁H₃₂O₂ | THC (tetrahydrocannabinol)C₂₁H₃₀O₂ |
| CAS number | CBG (cannabigerol)25654-31-3 (PubChem CID 5315659) | THC (tetrahydrocannabinol)1972-08-3 |
| Origin in the plant | CBG (cannabigerol)The neutral form of CBGA, known as the "mother cannabinoid" | THC (tetrahydrocannabinol)Forms when heat decarboxylates THCA |
| Other in-vitro targets (CBG, in words) | CBG (cannabigerol)Activates the α₂-adrenoceptor and blocks 5-HT₁A (Cascio 2010); acts on TRP channels (De Petrocellis 2011) | THC (tetrahydrocannabinol)— |
| US legal status (general, dated; not legal advice) | CBG (cannabigerol)Hemp-derived CBG is generally federally legal at ≤0.3% Δ⁹-THC (2018 Farm Bill); rules differ by state | THC (tetrahydrocannabinol)Federally controlled; rules differ by state |
| Standard drug test | CBG (cannabigerol)Not what the test looks for; the risk is trace THC in full-spectrum products | THC (tetrahydrocannabinol)Detected through its metabolite |
| Human evidence | CBG (cannabigerol)Very limited (see /cbg) | THC (tetrahydrocannabinol)Studied far more; this page makes no therapeutic claim |
The six rungs, and the words each one permits
- grade: Established
- Settled science — replicated human data, or biochemistry that is not in dispute. “is shown to”
- grade: Demonstrated
- Shown reproducibly in controlled experiments — typically laboratory (in-vitro) work. “has been shown to”
- grade: Emerging
- An early signal — preclinical (animal) work, or human evidence too limited to settle the question. “may · early evidence suggests”
- grade: Low
- Limited and low-confidence — sparse, indirect, or single-source data. “limited evidence · unclear”
- grade: Hypothesized
- Proposed and plausible — but not yet shown. “proposed mechanism”
- grade: Not supported
- Tested, and the evidence does NOT support it. This is a finding against the claim — not an absence of evidence. “evidence does not support”
- Catalogue in progress
- Not a rung: our registry holds nothing graded on the question yet. Absence is not evidence against.
A grade rates the support for a claim across the literature, never a single study. How we grade evidence.
- How to read a cell
- An oxblood ring holds the direction: a bar: blocks; a chevron: activates; a chevron with a bar: activates, then desensitises; two bars: damps activation. A gold ring with a dot: recorded in a review, direction qualified by the source, no rung of its own. A dashed frame: no graded interaction in our registry.
- CB1 cannabinoid receptor
- CBG: blocks (antagonist; drawn as a bar), in vitro grade: Demonstrated study type: In vitro Cascio 2010. THC: activates (partial agonist), in a review, no rung of its own study type: Review Pertwee 2008.
- CB2 cannabinoid receptor
- CBG: no graded interaction in our registry. THC: activates (partial agonist), in a review, no rung of its own study type: Review Pertwee 2008.
- α2-adrenoceptor
- CBG: activates (agonist; drawn as a chevron), in vitro grade: Demonstrated study type: In vitro Cascio 2010. THC: no graded interaction in our registry.
- 5-HT1A serotonin receptor
- CBG: blocks (antagonist; drawn as a bar), in vitro grade: Demonstrated study type: In vitro Cascio 2010. THC: no graded interaction in our registry.
- TRPV1 and TRPV2 ion channels
- CBG: activates, then desensitises (agonist, then desensitiser; drawn as a chevron with a bar), in vitro grade: Demonstrated study type: In vitro De Petrocellis 2011. THC: no graded interaction in our registry.
- TRPM8 ion channel
- CBG: blocks (antagonist; drawn as a bar), in vitro grade: Demonstrated study type: In vitro De Petrocellis 2011. THC: no graded interaction in our registry.
What the evidence settles
In the body and on the shelf the two sit far apart, and one difference outranks the rest.
- Intoxication. THC gets people high and CBG leaves them clear of it. Whether you formulate, label or sell, every other line in the table ranks below that one. Established
- Opposite CB₁ actions. The reason sits at a single receptor. THC's high, and the impairment that rides along with it, come from its partial agonism at CB₁ Established. In the lab CBG does the reverse, binding CB₁ as a competitive antagonist that blocks the receptor rather than switching it on (Cascio 2010). Demonstrated · in vitro
- Distinct chemistry. Two molecules, two routes through the plant: CBG is C₂₁H₃₂O₂ (CAS 25654-31-3), and THC is C₂₁H₃₀O₂ (CAS 1972-08-3). Established
- CBG's other in-vitro targets. CB₁ is only part of CBG's story. In cell studies it also activates the α₂-adrenoceptor and blocks the 5-HT₁A receptor (Cascio 2010), and it acts on several TRP ion channels (De Petrocellis 2011). Because α₂-adrenoceptors help regulate blood pressure, anyone taking cardiovascular medication should be cautious and consult a clinician. Demonstrated · in vitro
- Legal status (general, dated; not legal advice). The chemistry also decides the paperwork. In the US as of 2026, the 2018 Farm Bill makes hemp-derived CBG generally federally legal when the product holds ≤0.3% Δ⁹-THC, and THC above that line is federally controlled. State rules for both vary and keep shifting. [Legal snapshot · not legal advice]
- Drug testing. Standard panels hunt for a THC metabolite, and CBG sits outside their search. What trips a CBG customer is the trace THC that travels with full-spectrum formulations. Established (trace-THC positive risk · Low)
- Glaucoma / eye pressure (IOP). Our registry holds no primary study of CBG and intraocular pressure, in either direction, so a CBG eye-pressure claim has nothing under it. No primary evidence The record is empty rather than against the idea. THC and intraocular pressure is a separate clinical-research question, and we neither present nor endorse THC as a treatment for it.
- Human evidence. CBG's human record runs to very little; THC's runs far deeper, and we make a therapeutic claim for neither. Low
Common questions
Does CBG get you high like THC?
No, CBG doesn't intoxicate. The high belongs to THC, which switches on the CB₁ receptor as a partial agonist and brings impairment with it. In lab studies CBG blocks that same receptor instead, and the one small human trial of CBG in our registry reported no intoxication. Established
Is CBG or THC "stronger"?
Neither, because they sit on different scales. THC is intoxicating and psychoactive and CBG is not, and in the lab their main actions at CB₁ run in opposite directions: THC switches the receptor on and CBG blocks it. THC's effects are well documented; CBG's human record is minimal. Not medical advice. Established
Will CBG or THC show up on a drug test?
THC will, and CBG generally should not. Standard drug tests detect a THC metabolite, so THC use can produce a positive, while CBG itself sits outside what the test looks for. The catch is full-spectrum CBG, whose trace THC (≤0.3% Δ⁹-THC) can build up and trigger a positive. No product can promise a clean test. Established
Is CBG legal when THC isn't?
Often, depending on where you are and when you ask. In the US as of 2026, hemp-derived CBG is generally federally legal under the 2018 Farm Bill if the product contains ≤0.3% Δ⁹-THC, while THC above that threshold is federally controlled. State laws differ for both and keep changing. General information, not legal advice. [Legal snapshot · not legal advice]
Is CBG or THC better for glaucoma or eye pressure?
Neither has support here for glaucoma. For CBG our registry holds no primary study of eye pressure (intraocular pressure) in either direction, so the claim stands on air. THC is a different case: researchers have discussed short-lived pressure changes, and that remains a clinical research topic rather than a treatment we would put forward. Not medical advice. No primary evidence
Is CBG safer than THC?
That has not been shown. CBG spares users THC's impairment, and its one small human trial in our registry reported no intoxication, but safety is a wider question than getting high, and long-term use, drug interactions and higher doses remain poorly studied. Because CBG acts on α₂-adrenoceptors that help regulate blood pressure (Cascio 2010), consult a clinician if you take cardiovascular medication. Not medical advice. Low
Informational only — not our claims, and not advice. The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.
Before you act on what you have read
Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.
Each grade rates the support for a claim across the literature. It does not rate any single study. An effect in cells may never show up in people. The grades cover the studies checked up to 9 August 2026. This page is for information and is not medical advice.
Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.
Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event →Keep exploring
The compounds compared
More comparisons